Sonidegib

Category: Cancer



Sonidegib Overview

Sonidegib (INN), also known as LDE225 and marketed as Odomzo,[3] is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis.[4][5] Contents 1 Approvals and indications 2 Pharmacology 3 Development 4 Reference list Approvals and indications It was approved by the FDA for treating basal-cell carcinoma in July 2015[6][3] and is awaiting approval i...

Read more Sonidegib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sonidegib

Recent Sonidegib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sonidegib
  • Capsule: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Sonidegib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA